Published: June 30, 2026 at 7:57 am
A former key executive at Oxford Nanopore Technologies has been named CEO at fellow biotechnology firm Oxford BioDynamics Plc.
Oxford BioDynamics, also known as OBD, is looking to advance personalised healthcare through precision clinical diagnostic tests and EpiSwitch Orion, its cloud-based 3D genomics platform.
Targeting pharma and BioTech partners, it is now looking to incoming CEO Richard Compton to secure the sales necessary to the long-term viability of the business.